Drugs interactions for Vyepti®

  • 0 Major drug interactions
  • 1 Moderate drug interactions (including ingredients like Pozelimab)
  • 159 Minor drug interactions (including ingredients like Adalimumab, Aducanumab, Alemtuzumab)
160 interactions for Vyepti®
A therapy excluded from this list of known interactions does not necessarily mean that no interactions exist between that therapy and and Vyepti®.
Pozelimab
The serum concentration of Pozelimab can be decreased when it is combined with Eptinezumab.
Adalimumab
The risk or severity of adverse effects can be increased when Adalimumab is combined with Eptinezumab.
Aducanumab
The risk or severity of adverse effects can be increased when Aducanumab is combined with Eptinezumab.
Alemtuzumab
The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Eptinezumab.
Alirocumab
The risk or severity of adverse effects can be increased when Alirocumab is combined with Eptinezumab.
Amivantamab
The risk or severity of adverse effects can be increased when Eptinezumab is combined with Amivantamab.
Anifrolumab
The risk or severity of adverse effects can be increased when Anifrolumab is combined with Eptinezumab.
Ansuvimab
The risk or severity of adverse effects can be increased when Eptinezumab is combined with Ansuvimab.
Anthrax immune globulin human
The risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Eptinezumab.
Antilymphocyte immunoglobulin (horse)
The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Eptinezumab.
Antithymocyte immunoglobulin (rabbit)
The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Eptinezumab.
Asfotase alfa
The risk or severity of adverse effects can be increased when Asfotase alfa is combined with Eptinezumab.
Atezolizumab
The risk or severity of adverse effects can be increased when Atezolizumab is combined with Eptinezumab.
Atoltivimab
The risk or severity of adverse effects can be increased when Eptinezumab is combined with Atoltivimab.
Avelumab
The risk or severity of adverse effects can be increased when Avelumab is combined with Eptinezumab.
Axatilimab
The risk or severity of adverse effects can be increased when Eptinezumab is combined with Axatilimab.
Bamlanivimab
The risk or severity of adverse effects can be increased when Eptinezumab is combined with Bamlanivimab.
Basiliximab
The risk or severity of adverse effects can be increased when Basiliximab is combined with Eptinezumab.
Belimumab
The risk or severity of adverse effects can be increased when Belimumab is combined with Eptinezumab.
Benralizumab
The risk or severity of adverse effects can be increased when Benralizumab is combined with Eptinezumab.
Bevacizumab
The risk or severity of adverse effects can be increased when Bevacizumab is combined with Eptinezumab.
Bezlotoxumab
The risk or severity of adverse effects can be increased when Bezlotoxumab is combined with Eptinezumab.
Bimekizumab
The risk or severity of adverse effects can be increased when Bimekizumab is combined with Eptinezumab.
Blinatumomab
The risk or severity of adverse effects can be increased when Blinatumomab is combined with Eptinezumab.
Brentuximab vedotin
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Eptinezumab.
Brodalumab
The risk or severity of adverse effects can be increased when Brodalumab is combined with Eptinezumab.
Brolucizumab
The risk or severity of adverse effects can be increased when Eptinezumab is combined with Brolucizumab.
Burosumab
The risk or severity of adverse effects can be increased when Burosumab is combined with Eptinezumab.
Canakinumab
The risk or severity of adverse effects can be increased when Canakinumab is combined with Eptinezumab.
Caplacizumab
The risk or severity of adverse effects can be increased when Caplacizumab is combined with Eptinezumab.
Cemiplimab
The risk or severity of adverse effects can be increased when Eptinezumab is combined with Cemiplimab.
Certolizumab pegol
The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Eptinezumab.
Cetuximab
The risk or severity of adverse effects can be increased when Cetuximab is combined with Eptinezumab.
Cilgavimab
The risk or severity of adverse effects can be increased when Eptinezumab is combined with Cilgavimab.
Clesrovimab
The risk or severity of adverse effects can be increased when Eptinezumab is combined with Clesrovimab.
Conjugated estrogens
Conjugated estrogens may increase the thrombogenic activities of Eptinezumab.
Cosibelimab
The risk or severity of adverse effects can be increased when Eptinezumab is combined with Cosibelimab.
Crovalimab
The risk or severity of adverse effects can be increased when Eptinezumab is combined with Crovalimab.
Daratumumab
The risk or severity of adverse effects can be increased when Daratumumab is combined with Eptinezumab.
Denosumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Eptinezumab.
Digoxin Immune Fab (Ovine)
The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Eptinezumab.
Dinutuximab
The risk or severity of adverse effects can be increased when Dinutuximab is combined with Eptinezumab.
Donanemab
The risk or severity of adverse effects can be increased when Eptinezumab is combined with Donanemab.
Dostarlimab
The risk or severity of adverse effects can be increased when Eptinezumab is combined with Dostarlimab.
Dulaglutide
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Eptinezumab.
Dupilumab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Eptinezumab.
Durvalumab
The risk or severity of adverse effects can be increased when Durvalumab is combined with Eptinezumab.
Ebola Zaire vaccine (live, attenuated)
The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Eptinezumab.
Eculizumab
The risk or severity of adverse effects can be increased when Eculizumab is combined with Eptinezumab.
Eflapegrastim
The risk or severity of adverse effects can be increased when Eptinezumab is combined with Eflapegrastim.
Eftrenonacog alfa
The risk or severity of adverse effects can be increased when Eftrenonacog alfa is combined with Eptinezumab.
Elotuzumab
The risk or severity of adverse effects can be increased when Elotuzumab is combined with Eptinezumab.
Emapalumab
The risk or severity of adverse effects can be increased when Eptinezumab is combined with Emapalumab.
Emicizumab
The risk or severity of adverse effects can be increased when Emicizumab is combined with Eptinezumab.
Erenumab
The risk or severity of adverse effects can be increased when Erenumab is combined with Eptinezumab.
Esterified estrogens
Esterified estrogens may increase the thrombogenic activities of Eptinezumab.
Estetrol
Estetrol may increase the thrombogenic activities of Eptinezumab.
Estradiol
Estradiol may increase the thrombogenic activities of Eptinezumab.
Estradiol acetate
Estradiol acetate may increase the thrombogenic activities of Eptinezumab.
Estradiol cypionate
Estradiol cypionate may increase the thrombogenic activities of Eptinezumab.
Estradiol valerate
Estradiol valerate may increase the thrombogenic activities of Eptinezumab.
Estriol
Estriol may increase the thrombogenic activities of Eptinezumab.
Estrone sulfate
Estrone sulfate may increase the thrombogenic activities of Eptinezumab.
Ethinylestradiol
Ethinylestradiol may increase the thrombogenic activities of Eptinezumab.
Evolocumab
The risk or severity of adverse effects can be increased when Evolocumab is combined with Eptinezumab.
Fanolesomab
The risk or severity of adverse effects can be increased when Eptinezumab is combined with Fanolesomab.
Fremanezumab
The risk or severity of adverse effects can be increased when Eptinezumab is combined with Fremanezumab.
Galcanezumab
The risk or severity of adverse effects can be increased when Eptinezumab is combined with Galcanezumab.
Gemtuzumab ozogamicin
The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Eptinezumab.
Glofitamab
The risk or severity of adverse effects can be increased when Eptinezumab is combined with Glofitamab.
Golimumab
The risk or severity of adverse effects can be increased when Golimumab is combined with Eptinezumab.
Guselkumab
The risk or severity of adverse effects can be increased when Guselkumab is combined with Eptinezumab.
Hepatitis B immune globulin
The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Eptinezumab.
Human cytomegalovirus immune globulin
The risk or severity of adverse effects can be increased when Human cytomegalovirus immune globulin is combined with Eptinezumab.
Human immunoglobulin G
The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Eptinezumab.
Human Rho(D) immune globulin
The risk or severity of adverse effects can be increased when Human Rho(D) immune globulin is combined with Eptinezumab.
Human varicella-zoster immune globulin
The risk or severity of adverse effects can be increased when Human varicella-zoster immune globulin is combined with Eptinezumab.
Ibalizumab
The risk or severity of adverse effects can be increased when Ibalizumab is combined with Eptinezumab.
Ibritumomab tiuxetan
The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Eptinezumab.
Idarucizumab
The risk or severity of adverse effects can be increased when Idarucizumab is combined with Eptinezumab.
Inebilizumab
The risk or severity of adverse effects can be increased when Inebilizumab is combined with Eptinezumab.
Infliximab
The risk or severity of adverse effects can be increased when Infliximab is combined with Eptinezumab.
Inotuzumab ozogamicin
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Eptinezumab.
Ipilimumab
The risk or severity of adverse effects can be increased when Ipilimumab is combined with Eptinezumab.
Isatuximab
The risk or severity of adverse effects can be increased when Eptinezumab is combined with Isatuximab.
Ixekizumab
The risk or severity of adverse effects can be increased when Ixekizumab is combined with Eptinezumab.
Lanadelumab
The risk or severity of adverse effects can be increased when Eptinezumab is combined with Lanadelumab.
Lebrikizumab
The risk or severity of adverse effects can be increased when Lebrikizumab is combined with Eptinezumab.
Lecanemab
The risk or severity of adverse effects can be increased when Eptinezumab is combined with Lecanemab.
Linvoseltamab
The risk or severity of adverse effects can be increased when Eptinezumab is combined with Linvoseltamab.
Loncastuximab tesirine
The risk or severity of adverse effects can be increased when Eptinezumab is combined with Loncastuximab tesirine.
Maftivimab
The risk or severity of adverse effects can be increased when Eptinezumab is combined with Maftivimab.
Margetuximab
The risk or severity of adverse effects can be increased when Eptinezumab is combined with Margetuximab.
Marstacimab
The risk or severity of adverse effects can be increased when Eptinezumab is combined with Marstacimab.
Mepolizumab
The risk or severity of adverse effects can be increased when Mepolizumab is combined with Eptinezumab.
Mirvetuximab soravtansine
The risk or severity of adverse effects can be increased when Mirvetuximab Soravtansine is combined with Eptinezumab.
Mogamulizumab
The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Eptinezumab.
Mosunetuzumab
The risk or severity of adverse effects can be increased when Eptinezumab is combined with Mosunetuzumab.
Natalizumab
The risk or severity of adverse effects can be increased when Natalizumab is combined with Eptinezumab.
Necitumumab
The risk or severity of adverse effects can be increased when Necitumumab is combined with Eptinezumab.
Nemolizumab
The risk or severity of adverse effects can be increased when Eptinezumab is combined with Nemolizumab.
Nipocalimab
The serum concentration of Eptinezumab can be decreased when it is combined with Nipocalimab.
Nivolumab
The risk or severity of adverse effects can be increased when Nivolumab is combined with Eptinezumab.
Obiltoxaximab
The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Eptinezumab.
Obinutuzumab
The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Eptinezumab.
Ocrelizumab
The risk or severity of adverse effects can be increased when Ocrelizumab is combined with Eptinezumab.
Odesivimab
The risk or severity of adverse effects can be increased when Eptinezumab is combined with Odesivimab.
Ofatumumab
The risk or severity of adverse effects can be increased when Ofatumumab is combined with Eptinezumab.
Olaratumab
The risk or severity of adverse effects can be increased when Olaratumab is combined with Eptinezumab.
Omalizumab
The risk or severity of adverse effects can be increased when Omalizumab is combined with Eptinezumab.
Palivizumab
The risk or severity of adverse effects can be increased when Palivizumab is combined with Eptinezumab.
Panitumumab
The risk or severity of adverse effects can be increased when Panitumumab is combined with Eptinezumab.
Pembrolizumab
The risk or severity of adverse effects can be increased when Pembrolizumab is combined with Eptinezumab.
Penpulimab
The risk or severity of adverse effects can be increased when Eptinezumab is combined with Penpulimab.
Pertuzumab
The risk or severity of adverse effects can be increased when Pertuzumab is combined with Eptinezumab.
Polatuzumab vedotin
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Eptinezumab.
Ramucirumab
The risk or severity of adverse effects can be increased when Ramucirumab is combined with Eptinezumab.
Ranibizumab
The risk or severity of adverse effects can be increased when Ranibizumab is combined with Eptinezumab.
Ravulizumab
The risk or severity of adverse effects can be increased when Ravulizumab is combined with Eptinezumab.
Raxibacumab
The risk or severity of adverse effects can be increased when Raxibacumab is combined with Eptinezumab.
Relatlimab
The risk or severity of adverse effects can be increased when Eptinezumab is combined with Relatlimab.
Reslizumab
The risk or severity of adverse effects can be increased when Reslizumab is combined with Eptinezumab.
Risankizumab
The risk or severity of adverse effects can be increased when Eptinezumab is combined with Risankizumab.
Rituximab
The risk or severity of adverse effects can be increased when Rituximab is combined with Eptinezumab.
Romosozumab
The risk or severity of adverse effects can be increased when Romosozumab is combined with Eptinezumab.
Rozanolixizumab
The risk or severity of adverse effects can be increased when Eptinezumab is combined with Rozanolixizumab.
Sacituzumab govitecan
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Eptinezumab.
Sarilumab
The risk or severity of adverse effects can be increased when Sarilumab is combined with Eptinezumab.
Secukinumab
The risk or severity of adverse effects can be increased when Secukinumab is combined with Eptinezumab.
Siltuximab
The risk or severity of adverse effects can be increased when Siltuximab is combined with Eptinezumab.
Sotatercept
The risk or severity of adverse effects can be increased when Sotatercept is combined with Eptinezumab.
Sotrovimab
The risk or severity of adverse effects can be increased when Eptinezumab is combined with Sotrovimab.
Spesolimab
The risk or severity of adverse effects can be increased when Eptinezumab is combined with Spesolimab.
Sutimlimab
The risk or severity of adverse effects can be increased when Eptinezumab is combined with Sutimlimab.
Synthetic Conjugated Estrogens, A
Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Eptinezumab.
Synthetic Conjugated Estrogens, B
Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Eptinezumab.
Tafasitamab
The risk or severity of adverse effects can be increased when Eptinezumab is combined with Tafasitamab.
Telisotuzumab vedotin
The risk or severity of adverse effects can be increased when Eptinezumab is combined with Telisotuzumab vedotin.
Teplizumab
The risk or severity of adverse effects can be increased when Teplizumab is combined with Eptinezumab.
Teprotumumab
The risk or severity of adverse effects can be increased when Teprotumumab is combined with Eptinezumab.
Tetanus immune globulin, human
The risk or severity of adverse effects can be increased when Tetanus immune globulin, human is combined with Eptinezumab.
Tezepelumab
The risk or severity of adverse effects can be increased when Eptinezumab is combined with Tezepelumab.
Tildrakizumab
The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Eptinezumab.
Tislelizumab
The risk or severity of adverse effects can be increased when Eptinezumab is combined with Tislelizumab.
Tisotumab vedotin
The risk or severity of adverse effects can be increased when Eptinezumab is combined with Tisotumab vedotin.
Tixagevimab
The risk or severity of adverse effects can be increased when Eptinezumab is combined with Tixagevimab.
Tocilizumab
The risk or severity of adverse effects can be increased when Tocilizumab is combined with Eptinezumab.
Toripalimab
The risk or severity of adverse effects can be increased when Eptinezumab is combined with Toripalimab.
Tralokinumab
The risk or severity of adverse effects can be increased when Tralokinumab is combined with Eptinezumab.
Trastuzumab
The risk or severity of adverse effects can be increased when Trastuzumab is combined with Eptinezumab.
Trastuzumab deruxtecan
The risk or severity of adverse effects can be increased when Eptinezumab is combined with Trastuzumab deruxtecan.
Trastuzumab emtansine
The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Eptinezumab.
Tremelimumab
The risk or severity of adverse effects can be increased when Tremelimumab is combined with Eptinezumab.
Ublituximab
The risk or severity of adverse effects can be increased when Ublituximab is combined with Eptinezumab.
Ustekinumab
The risk or severity of adverse effects can be increased when Ustekinumab is combined with Eptinezumab.
Vedolizumab
The risk or severity of adverse effects can be increased when Vedolizumab is combined with Eptinezumab.
Vilobelimab
The risk or severity of adverse effects can be increased when Eptinezumab is combined with Vilobelimab.
Zanidatamab
The risk or severity of adverse effects can be increased when Eptinezumab is combined with Zanidatamab.
Zenocutuzumab
The risk or severity of adverse effects can be increased when Eptinezumab is combined with Zenocutuzumab.
Zolbetuximab
The risk or severity of adverse effects can be increased when Eptinezumab is combined with Zolbetuximab.